Akorn, Inc. Responds To FDA Draft Guidance For Industry On Bioequivalence Recommendation For Vancomycin HCl

Akorn, Inc. (NASDAQ: AKRX) provided the following response regarding FDA’s draft guidance on vancomycin hydrochloride (HCl) capsules. The Food and Drug Administration (FDA) has posted draft guidance for establishing bioequivalence (BE) for vancomycin HCl capsules.

More: continued here

Filed under: Pharma Industry on January 3rd, 2009